Incyte up after European Commission expands use of cancer drug
ReutersDec 17, 2025 4:40 PM
Shares of drugmaker Incyte INCY.O rise 1.9% to $98.83
Incyte says that the European Commission has approved its cancer drug Minjuvi in combination with lenalidomide and rituximab
The new approval expands the use for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy
FL is a type of cancer that begins in the lymph system, a part of the immune system
Minjuvi was already approved by the EC in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Including session moves, stock up 42.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Global Flight to Safety Intensifies as Gold, Silver, and Platinum Hit New Highs — ‘Currency Wars’ Author Predicts $10,000 Gold and $200 Silver
TradingKey - Since the start of 2025, silver, which offers both investment attributes and industrial utility, has surged by approximately 150%.TradingKey
Fri, Dec 26
TradingKey 2025 Markets Recap & Outlook | Bitcoin Price Repeatedly Hits New Highs, 2026 Can BTC Write Another Legend?
Multiple tailwinds in 2025 propelled Bitcoin to new highs, but many of these positives have already been priced in. In 2026, Bitcoin faces challenges such as liquidity tightening, as well as regulatory and monetary policy uncertainties. Wall Street is divided on Bitcoin's future outlook, with targetTradingKey
Fri, Dec 26
TradingKey 2025 Markets Recap & Outlook | Global Central Banks 2026 amid Post‑Easing Recovery and Diverging Paths
TradingKey - In 2025, major global central banks will largely maintain an accommodative stance, but the policy pace will decelerate notably. As the easing cycle draws to a close, how will global monetary policy evolve?TradingKey
Thu, Dec 25
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
